SEC Comment Letter for RAPT Therapeutics, Inc. (RAPT) (CIK 0001673772) (RAPT) — Jun 27, 2022
RAPT Therapeutics, Inc. (RAPT) (CIK 0001673772)
Date: June 27, 2022 · CIK: 0001673772 · Accession: 0000000000-22-006862
AI Filing Summary & Sentiment
File numbers found in text: 333-265812
Letter
United States securities and exchange commission logo June 27, 2022 Brian Wong, M.D., Ph.D. President and Chief Executive Officer RAPT Therapeutics, Inc. 561 Eccles Avenue South San Francisco, California, 94080 Re:RAPT Therapeutics, Inc. Registration Statement on Form S-3 Filed June 24, 2022 File No. 333-265812 Dear Dr. Wong: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Courtney M.W. Tygesson, Esq.
Show Raw Text
United States securities and exchange commission logo
June 27, 2022
Brian Wong, M.D., Ph.D.
President and Chief Executive Officer
RAPT Therapeutics, Inc.
561 Eccles Avenue
South San Francisco, California, 94080
Re:RAPT Therapeutics, Inc.
Registration Statement on Form S-3
Filed June 24, 2022
File No. 333-265812
Dear Dr. Wong:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Courtney M.W. Tygesson, Esq.